Photo from wikipedia
The efficacy of daratumumab (DARA) both as a monotherapy and in combination with standard‐of‐care regimens in multiple myeloma (MM) has been established in clinical trials. This article presents a retrospective… Click to show full abstract
The efficacy of daratumumab (DARA) both as a monotherapy and in combination with standard‐of‐care regimens in multiple myeloma (MM) has been established in clinical trials. This article presents a retrospective analysis of the safety and efficacy of DARA in combination with pomalidomide (POM) and dexamethasone (ie, daratumumab, pomalidomide, and dexamethasone [DARA‐POM‐D]) and, more importantly, the long‐term follow‐up of a cohort that was naive to DARA and POM as well as a cohort in which the utility of re‐treatment was evaluated among patients who were DARA‐ and/or POM‐refractory.
Journal Title: Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!